Joanna Szafraniec-Szczęsny

Dr. Joanna Szafraniec-Szczęsny

Department of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, Jagiellonian University Medical College
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2018 in Pharmaceutical Research
Verified
Journal Article
Open access
PDF file
Witold JamrózWitold Jamróz
Witold Jamróz
Joanna Szafraniec-SzczęsnyJoanna Szafraniec-Szczęsny
Joanna Szafraniec-Szczęsny
Mateusz KurekMateusz Kurek
Mateusz Kurek
RJRenata Jachowicz
Renata Jachowicz
Growing demand for customized pharmaceutics and medical devices makes the impact of additive manufacturing increased rapidly in recent years. The 3D printing has become one of the most revolutionary and powerful tool serving as a technology of precise manufacturing of individually developed dosage forms, tissue engineering and disease modeling. The current achievements include multifunctional drug delivery systems with accelerated release characteristic, adjustable and personalized dosage forms, implants and phantoms corresponding to specific patient anatomy as well as cell-based materials for regenerative medicine. This review summarizes the newest achievements and challenges of additive manufacturing in the field of pharmaceutical and biomedical research that have been published since 2015. Currently developed techniques of 3D printing are briefly described while comprehensive analysis of extrusion-based methods as the most intensively investigated is provided. The issue of printlets attributes, i.e. shape and size is described with regard to personalized dosage forms and medical devices manufacturing. The undeniable benefits of 3D printing are highlighted, however a critical view resulting from the limitations and challenges of the additive manufacturing is also included. The regulatory issue is pointed as well.

1 November 2017 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
Witold JamrózWitold Jamróz
Witold Jamróz
Mateusz KurekMateusz Kurek
Mateusz Kurek
EŁEwelina Łyszczarz
Ewelina Łyszczarz
Joanna Szafraniec-SzczęsnyJoanna Szafraniec-Szczęsny
Joanna Szafraniec-Szczęsny
Justyna Knapik-KowalczukJustyna Knapik-Kowalczuk
Justyna Knapik-Kowalczuk
RJRenata Jachowicz
Renata Jachowicz

22 July 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
EŁEwelina Łyszczarz
Ewelina Łyszczarz
Witold BrniakWitold Brniak
Witold Brniak
Joanna Szafraniec-SzczęsnyJoanna Szafraniec-Szczęsny
Joanna Szafraniec-Szczęsny
Tomasz MajkaTomasz Majka
Tomasz Majka
DMDorota Majda
Dorota Majda
RJRenata Jachowicz
Renata Jachowicz
Orodispersible films (ODFs) address the needs of pediatric and geriatric patients and people with swallowing difficulties due to fast disintegration in the mouth. Typically, they are obtained using the solvent casting method, but other techniques such as 3D printing and electrospinning have already been investigated. The decision on the manufacturing method is of crucial importance because it affects film properties. This study aimed to compare electrospun ODFs containing aripiprazole and polyvinyl alcohol with films prepared using casting and 3D printing methods. Characterization of films included DSC and XRD analysis, microscopic analysis, the assessment of mechanical parameters, disintegration, and dissolution tests. Simplified stability studies were performed after one month of storage. All prepared films met acceptance criteria for mechanical properties. Electrospun ODFs disintegrated in 1.0 s, which was much less than in the case of other films. Stability studies have shown the sensitivity of electrospun films to the storage condition resulting in partial recrystallization of ARP. These changes negatively affected the dissolution rate, but mechanical properties and disintegration time remained at a desirable level. The results demonstrated that electrospun fibers are promising solutions that can be used in the future for the treatment of patients with swallowing problems.

1 October 2018 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
Witold JamrózWitold Jamróz
Witold Jamróz
Mateusz KurekMateusz Kurek
Mateusz Kurek
ACAnna Czech
Anna Czech
Joanna Szafraniec-SzczęsnyJoanna Szafraniec-Szczęsny
Joanna Szafraniec-Szczęsny
KGKarolina Gawlak
Karolina Gawlak
RJRenata Jachowicz
Renata Jachowicz

7 March 2017 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
JSJustyna Szczurek
Justyna Szczurek
MRMarzena Rams-Baron
Marzena Rams-Baron
Justyna Knapik-KowalczukJustyna Knapik-Kowalczuk
Justyna Knapik-Kowalczuk
AAAgata Antosik-Rogóż
Agata Antosik-Rogóż
Joanna Szafraniec-SzczęsnyJoanna Szafraniec-Szczęsny
Joanna Szafraniec-Szczęsny
MPMarian Paluch
Marian Paluch

1 February 2020 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
Witold JamrózWitold Jamróz
Witold Jamróz
MKMateusz Kurek
Mateusz Kurek
Joanna Szafraniec-SzczęsnyJoanna Szafraniec-Szczęsny
Joanna Szafraniec-Szczęsny
ACAnna Czech
Anna Czech
KGKarolina Gawlak
Karolina Gawlak
RJRenata Jachowicz
Renata Jachowicz